Evidence map›Paper›PMID 34854410›Full record

ReviewIndian journal of pharmacology

Evidences suggesting a possible role of Vitamin D in COVID 19: The missing link.

Shruti Singh, C M Singh, Alok Ranjan, Sanjeev Kumar, Dheeraj Kumar Singh

Open access · greenAbstract readReview
In one paragraph

Review in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shruti SinghDepartment of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India.
C M SinghDepartment of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
Alok RanjanDepartment of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India.
Sanjeev KumarDepartment of CTVS, All India Institute of Medical Sciences, Patna, Bihar, India.
Dheeraj Kumar SinghDepartment of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India.
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 is spreading like wildfire with no specific recommended treatment in sight. While some risk factors such as the presence of comorbidities, old age, and ethnicity have been recognized, not a lot is known about who the virus will strike first or impact more. In this hopeless scenario, exploration of time-tested facts about viral infections, in general, seems to be a sound basis to prop further research upon. The fact that immunity and its various determinants (e.g., micronutrients, sleep, and hygiene) have a crucial role to play in the defense against invading organisms, may be a good starting point for commencing research into these as yet undisclosed territories. Herein, the excellent immunomodulatory, antiviral, and anti-inflammatory roles of Vitamin D necessitate thorough investigation, particularly in COVID-19 perspective. This article reviews mechanisms and evidence suggesting the role Vitamin D plays in people infected by the newly identified COVID-19 virus. For this review, we searched the databases of Medline, PubMed, and Embase. We studied several meta-analyses and randomized controlled trials evaluating the role of Vitamin D in influenza and other contagious viral infections. We also reviewed the circumstantial and anecdotal evidence connecting Vitamin D with COVID-19 emerging recently. Consequently, it seems logical to conclude that the immune-enhancing, antiviral, anti-inflammatory, and lung-protective role of Vitamin D can be potentially lifesaving. Hence, Vitamin D deserves exhaustive exploration through rigorously designed and controlled scientific trials. Using Vitamin D as prophylaxis and/or chemotherapeutic treatment of COVID-19 infection is an approach worth considering. In this regard, mass assessment and subsequent supplementation can be tried, especially considering the mechanistic evidence in respiratory infections, low potential for toxicity, and widespread prevalence of the deficiency of Vitamin D affecting many people worldwide.

Indexed as

COVID-19 Drug TreatmentAnimalsAntiviral AgentsCOVID-19Host-Pathogen InteractionsHumansImmunityImmunomodulating AgentsLungRisk AssessmentRisk FactorsSARS-CoV-2Treatment OutcomeVitamin DVitamin D DeficiencyVitaminsAntiviral AgentsImmunomodulating AgentsVitamin DVitaminsCOVID-19prophylaxistreatmentviral respiratory illnessVitamin D

Identifiers

PMID34854410
PMCPMC8641745
OpenAlexW3216016078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.